Filing Flows › Alkermes (ALKS) › Q2 2026
Alkermes (ALKS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 28, 2026
Alkermes (ALKS) reported revenue of $496M for the second quarter 2026 (Q2 2026), +27% from a year earlier and +26% from the quarter before. Operating margin was 3.7%, net earnings $501K (0.1% of revenue).
Alkermes, Q2 2026: revenue $496M (+27% year over year), operating margin 3.7%, net earnings $501K, operating cash flow $145M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $496M | +26% | +27% |
| Operating profit | $18.4M | — | -80% |
| Net earnings | $501K | — | -99% |
| Operating cash flow | $145M | — | -3% |
| Free cash flow | $137M | — | -0.1% |
What changed
Revenue was $496.0M in Q2 2026, up 27% year over year and up 26% from the previous quarter. Vivitrol was the largest line at 25% of revenue. LYBALVI added $9.7M year over year (up 12%), 9% of the total change. Royalty declined 5%.
Operating profit was $18.4M, a 3.7% margin (down 20.1 points year over year). Operating profit fell $74.6M even though revenue rose $105.4M versus Q2 2025, so costs grew faster than sales. Total costs grew 60% against revenue growth of 27%. The fastest-growing cost line was Cost of revenue (+98%). Net earnings were $501K, down 99% year over year.
Operating cash flow was $145.2M (down 3% year over year), 28979% of net earnings. Non-cash charges added back $30.3M of depreciation and amortization and $31.1M of share-based compensation. Working capital and other items added $83.3M. Capital expenditures of $8.1M left free cash flow of $137.0M.
Questions
What was Alkermes' revenue in the second quarter 2026?
Alkermes (ALKS) reported revenue of $496M for the second quarter 2026 (Q2 2026), +27% from a year earlier and +26% from the quarter before.
Was Alkermes profitable in the second quarter 2026?
Operating profit was $18.4M (3.7% of revenue) and net earnings $501K.
Source: Alkermes 10-Q on SEC EDGAR.